Luseogliflozin restores GIP responsiveness in diabetic male mice with preserved β‐cell function
Physiological Reports · 2026-07 · 14 (13)
DOI: 10.14814/phy2.71016 ↗At a glance
Journal article in Physiological Reports, published online on 2026-07-11. Written by Quan Yingyue and 4 co-authors. Institution: Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan. Major MEDLINE topics: Insulin-Secreting Cells, Gastric Inhibitory Polypeptide, Sorbitol, Diabetes Mellitus, Experimental. 27 references. The full text is freely available (open access, CC BY 4.0). Funded by: Taisho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Company.
Abstract (original language)
Impaired glucose‐dependent insulinotropic polypeptide (GIP)‐induced insulin secretion is a characteristic feature of type 2 diabetes, whereas glucagon‐like peptide‐1 (GLP‐1) responsiveness is relatively preserved. Our previous study proposed that chronic β‐cell depolarization alters G protein signaling and contributes to this differential incretin responsiveness, but whether glucose lowering by sodium–glucose cotransporter 2 inhibition restores incretin responsiveness remains unclear. We investigated the effects of chronic luseogliflozin treatment on incretin responsiveness in two diabetic mouse models, KK‐Ay mice with preserved residual β‐cell function and streptozotocin/high‐fat diet‐induced diabetic mice with severe β‐cell impairment. Luseogliflozin improved glycemic control in both models without marked changes in body weight or plasma insulin levels. In KK‐Ay mice, luseogliflozin restored the glucose‐lowering effect of GIP during GIP‐preload glucose tolerance test. In contrast, this effect was not observed in streptozotocin/high‐fat diet‐induced diabetic mice, suggesting that preserved residual β‐cell function is required for recovery of GIP responsiveness. Ex vivo analyses using isolated islets further showed that chronic luseogliflozin treatment altered incretin‐stimulated insulin secretion, including attenuation of enhanced GLP‐1 responsiveness under diabetic conditions. These findings suggest that luseogliflozin may partially normalize aberrant β‐cell incretin signaling and restore GIP responsiveness when sufficient β‐cell function remains.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Division of Diabetes and Endocrinology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
- Division of Molecular and Metabolic Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
- Laboratory of Animal Breeding and Genetics, Division of Applied Biosciences, Graduate School of Agriculture, Kyoto University, Kyoto, Japan.
- Division of Metabolic Diseases, Department of Translational Medical Science, Kobe University Graduate School of Medicine, Kobe, Japan.
ORCID profiles: Kenji Sugawara
Funding
- Taisho Pharmaceutical Co., Ltd.
- Taisho Toyama Pharmaceutical Company
Cite
APA
Yingyue, Q., Takahashi, H., Yokoi, N., Ogawa, W., & Sugawara, K. (2026). Luseogliflozin restores GIP responsiveness in diabetic male mice with preserved β‐cell function. Physiological Reports, 14(13). https://doi.org/10.14814/phy2.71016
Vancouver
Yingyue Q, Takahashi H, Yokoi N, Ogawa W, Sugawara K. Luseogliflozin restores GIP responsiveness in diabetic male mice with preserved β‐cell function. Physiological Reports. 2026;14(13). doi:10.14814/phy2.71016
BibTeX
@article{Yingyue2026,
author = {Yingyue, Quan and Takahashi, Harumi and Yokoi, Norihide and Ogawa, Wataru and Sugawara, Kenji},
title = {Luseogliflozin restores GIP responsiveness in diabetic male mice with preserved β‐cell function},
journal = {Physiological Reports},
year = {2026},
volume = {14},
number = {13},
doi = {10.14814/phy2.71016}
}
EUVIMED